Reven Pharmaceuticals

RJX is a rationally designed proprietary composition of buffered acid products, electrolyte components, and high dose micro-nutrients currently being evaluated by the FDA for several potentially life-saving indications mainly caused by inflammation and dysfunctional immune response.  Some of these life-saving therapeutic uses include rare diseases currently lacking any viable treatment options.

How it Works

This unique pharmaceutical platform has potent anti-oxidant and anti-inflammatory activity and an excellent tissue distribution capacity with very favorable animal and human pharmacology. RJX can impact COVID-19 as well as other viral threats requiring inflammatory cytokines such as TGF-beta.

“Our goal is to impact multiple disease indications stemming from inflammation ranging from cancer to cardiovascular disease in the same way antibiotics impacted infectious disease when they were discovered nearly a century ago.”
Michael Volk
Founder & CSO
Interested in Learning More?